Charles (Chuck) Drake, M.D., Ph.D. is Vice President, Immuno-oncology (I-O) at Janssen Research & Development, LLC. In this position, he is responsible for leading the I-O team to further enhance the scientific strategy required to deliver the portfolio of I-O and cell-based oncology therapeutics, as well as building a robust pipeline of next-generation compounds. Dr. Drake is a physician-scientist whose research and clinical activities have focused on understanding the biology of immune cells in the tumor microenvironment and translating those findings into cutting-edge clinical trials in the study of patients with prostate, kidney, and bladder cancer.
Prior to joining Janssen Research & Development, Dr. Drake led the genitourinary oncology program at the Herbert Irving Cancer Center, Columbia University Medical Center, New York Presbyterian Hospital. He was also named the Milstein Family Professor of Medicine and Urology and served as the Associate Director for Clinical Research at the Cancer Center.
Dr. Drake founded Columbia’s Human Immune Monitoring Core, which provides state-of-the-art analytic technologies for the study of human cancer. At Columbia University, he and his colleagues built a strong portfolio of more than 30 immunotherapy trials, including a number of first-in-human studies in patients with prostate genitourinary cancers, many based on his laboratory research. Previously, he served as the Co-director of the Cancer Immunology Program at Johns Hopkins Kimmel Cancer Center.
Dr. Drake received his bachelor’s and master’s degrees in Biomedical Engineering from Rutgers University. He earned his medical degree from the University of Colorado Medical Science Training Program and received his doctorate in Immunology from the National Jewish Research Center. He completed his residency through the Osler Medical Residency Training Program at Johns Hopkins and finished his fellowship in Medical Oncology at Johns Hopkins as well. Dr. Drake is board-certified in medical oncology.
Sessions: